Antiprotozoal imidazopyridine compounds
Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidial agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
1. A compound having the formula (I):
or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 1 is hydrogen, methyl or fluoro;
R 2 is hydrogen or methyl;
R 3 is selected from -L-NR c R d , —C(OH)R b —CH 2 —NR c R d , [N—(C 1-4 ) alkyl]piperidinyl, piperidin-4-yl, [N—(C 1-4 ) alkyl]piperidin-4-yl, [N-methyl]piperidin-4-yl, [N-ethyl]piperidin-4-yl,
L is selected from —(CR a R b ) 2-5 — and
wherein one —(CR a R b ) represents a 1,1-(C 3-6 cycloalkyl),
R a and R b are independently selected from hydrogen, OH, F, and C 1-4 alkyl,
provided that when R a is OH, the R b attached to the C is hydrogen or C 1-4 alkyl;
or R a and R b , together with the C to which they are attached, form a C 3-6 cycloalkyl;
R c and R d are independently selected from hydrogen and C 1-4 alkyl;
n and m are independently 0, 1, 2, 3 or 4, provided that n+m=2, 3, or 4;
q is 1 or 2; and
p is 1,2 or 3.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
3. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
4. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
5. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
6. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
7. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
8. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is —C(OH)R b —CH 2 —NR c R d .
9. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is [N—(C 1-4 )alkyl]piperidinyl.
10. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is piperidin-4-yl.
11. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is [N—(C 1-4 ) alkyl]piperidin-4-yl.
12. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is [N-methyl]piperidin-4-yl.
13. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
R 3 is [N-ethyl]piperidin-4-yl.
14. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
15. The compound according to claim 1 , or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
L is —(CR a R b ) 2-5 —, and one —(CR a R b ) represents a 1,1-(C 3-6 cycloalkyl).